Inhibikase Q2 net loss widens on higher R&D, SG&A costs

Inhibikase Therapeutics

11/08/2026 21:10

Overview
U.S. clinical-stage pharma's Q2 net loss widened yr/yr on higher R&D and SG&A costs
Company raised $50 mln in July via share sale to RA Capital to fund Phase 3 trial
IKT-001 granted FDA Orphan Drug Designation, offering potential development incentives

Outlook
Company expects cash reserves to support operations through topline data readout in Phase 3 study
Inhibikase continues regulatory submissions for Phase 3 IMPROVE-PAH trial in additional countries
Company says Orphan Drug Designation may provide incentives and market exclusivity upon approval

Result Drivers
HIGHER R&D SPENDING - Co attributed increased Q2 research and development expenses to advancement of its global Phase 3 IMPROVE-PAH clinical trial for IKT-001
INCREASED SG&A COSTS - Q2 selling, general and administrative expenses rose yr/yr, reflecting higher operating costs

Company press release: ID:nGNX2PdrZM

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.11
 
Q2 Net Loss
 
$19.60 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Inhibikase Therapeutics, Inc. is $6.00, about 143.9% above its August 10 closing price of $2.46

Reuters Recommended Reads
Aug 11 - LB Pharmaceuticals Q2 net loss widens on higher R&D costs
Aug 10 - Perspective Therapeutics Q2 net loss widens on higher R&D costs
Aug 11 - Sagimet Biosciences Q2 net loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)